Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
45 studies found for:    "Anthrax"
Show Display Options
Rank Status Study
1 Completed A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults
Condition: Anthrax
Interventions: Biological: Anthrax;   Biological: Alhdryogel or PBS
2 Completed Anthrax-rPA: Safety, Tolerability, Immunogenicity
Condition: Anthrax
Intervention: Biological: Recombinant Protective Antigen, Anthrax Vaccine Adsorbed
3 Unknown  A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
Condition: Anthrax Infection
Interventions: Biological: AVA;   Biological: Ad4-PA-1;   Biological: Ad4-PA-GPI-1
4 Completed Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin
Condition: Anthrax
Intervention: Drug: Anthrax Immune Globulin
5 Completed Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
Condition: Anthrax
Interventions: Biological: Anthrax Immune Globulin Intravenous (AIGIV);   Biological: Gamunex
6 Completed Anthrax Vaccine Clinical Trials
Condition: Anthrax
Interventions: Drug: Anthrax Vaccine;   Procedure: Blood Chemistry;   Procedure: Hematology;   Procedure: Urinalysis
7 Recruiting Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Condition: Anthrax
8 Completed Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed
Condition: Bacillus Anthracis (Anthrax)
Interventions: Biological: AVA;   Biological: rPA vaccine containing alhydrogel
9 Completed PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine
Condition: Anthrax
Intervention: Biological: PA83-FhCMB
10 Completed
Has Results
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Condition: Anthrax
Interventions: Biological: AV7909;   Biological: BioThrax
11 Completed Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum
Condition: Symptoms of Inhalational Anthrax
Intervention: Biological: NP-015
12 Completed Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine
Condition: Prevention of Anthrax Infection
Intervention: Biological: rPA102 Vaccine
13 Completed Efficacy and Safety of Anthrax Vaccine, GC1109
Condition: Anthrax
Interventions: Biological: Low-dose GC1109;   Biological: High-dose GC1109;   Biological: Low-dose Placebo;   Biological: High-dose Placebo
14 Active, not recruiting A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects
Condition: Anthrax
Intervention: Biological: Px563L, RPA563, or placebo
15 Completed Monoclonal Antibody for Treatment of Inhalation Anthrax
Condition: Bacillus Anthracis (Anthrax)
Interventions: Drug: Ciprofloxacin 500 mg;   Drug: ETI-204 (Anthim)
16 Terminated UMD rPA Regimen Trial in Adults
Condition: Bacillus Anthracis (Anthrax)
Interventions: Biological: Anthrax vaccine absorbed made from Bacillus anthracis (AVA);   Biological: Recombinant protein antigen (rPA) made from Bacillus anthrax;   Biological: Recombinant protein antigen (rPA) made from Escherichia coli
17 Completed
Has Results
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
Condition: Bacillus Anthracis (Anthrax)
Intervention: Biological: BioThrax®
18 Completed Phase II Study of Range and Schedule of rPA Doses
Condition: Prevention of Bacillus Anthracis (Anthrax) Infection
Intervention: Biological: rPA vaccine containing alhydrogel
19 Completed
Has Results
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Condition: Bacillus Anthracis (Anthrax) Infection
Interventions: Biological: BioThrax;   Biological: AV7909 Formulation 1;   Biological: AV7909 Formulation 2;   Biological: AV7909 Formulation 3;   Biological: AV7909 Formulation 4;   Drug: Control
20 Suspended A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
Condition: Anthrax
Interventions: Biological: rPA vaccine containing alhydrogel 1.0 mL;   Drug: Normal Saline;   Biological: rPA vaccine containing alhydrogel 0.5 mL;   Biological: rPA vaccine containing alhydrogel 0.3 mL

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.